Characterization of a human breast cancer cell line, MCF-7/RU58 R-1, resistant to the pure antiestrogen RU 58,668

Breast Cancer Research and Treatment

Volumn 91, Issue 2, 2005, Pages 133-144

  Fog, C K ^a   Christensen, I J ^b   Lykkesfeldt, A E ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Antiestrogen resistance; Breast cancer; Endocrine therapy; Estrogen receptor; ICI 182,780; PSK 3668; Pure antiestrogens; RU 58,668; Tamoxifen

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL] ESTRADIOL; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; ANTIESTROGEN; CONNECTIVE TISSUE GROWTH FACTOR; ESTROGEN; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; PROGESTERONE RECEPTOR; PROTEIN BCL 2; SOMATOMEDIN C RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL CULTURE; CELL STRAIN MCF 7; CONTROLLED STUDY; CROSS RESISTANCE; DRUG MECHANISM; DRUG WITHDRAWAL; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; RECEPTORS, ESTROGEN;

EID: 18844379920     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-004-5871-y     Document Type: Article

References (46)

1. S Ali RC Coombes 2002 Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 101 112
2. P Van de Velde F Nique F Bouchoux J Bremaud MC Hameau D Lucas C Moratille S Viet D Philibert G Teutsch 1994 RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice J Steroid Biochem Mol Biol 48 187 196
3. P Van de Velde F Nique J Bremaud MC Hameau D Philibert G Teutsch 1995 Exploration of the therapeutic potential of the antiestrogen RU 58668 in breast cancer treatment Ann NY Acad Sci 761 164 175
4. VC Jordan 2003 Antiestrogens and selective estrogen receptor modulators as multifunctional medicines 2. Clinical considerations and new agents J Med Chem 46 1081 1111
5. C Morris A Wakeling 2002 Fulvestrant ('Faslodex') - a new treatment option for patients progressing on prior endocrine therapy Endocr Relat Cancer 9 267 276
6. JF Robertson CK Osborne A Howell SE Jones L Mauriac M Ellis UR Kleeberg SE Come I Vergote S Gertler A Buzdar A Webster C Morris 2003 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials Cancer 98 229 238
7. Vergote I: Postmenopausal woman with advanced breast cancer who have progresed after Fulvestrant (Faslodex) remain sensitive to other endocrine agents. Eu J Cancer 38 (Suppl 3), S96-abstract 216, 2003
8. AE Wakeling M Dukes J Bowler 1991 A potent specific pure antiestrogen with clinical potential Cancer Res 51 3867 3873
9. J Devin-Leclerc X Meng F Delahaye P Leclerc EE Baulieu MG Catelli 1998 Interaction and dissociation by ligands of estrogen receptor and HSP90: the antiestrogen RU 58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm Mol Endocrinol 12 842 854
10. S Dauvois R White MG Parker 1993 The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling J Cell Sci 106 1377 1388
11. V Marsaud A Gougelet S Maillard JM Renoir 2003 Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ER alpha), differentially affect ER alpha extractability, proteasome-mediated stability and transcriptional activity in human breast cancer cells Mol Endocrinol 17 2013 2027
12. S Dauvois PS Danielian R White MG Parker 1992 Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover Proc Natl Acad Sci USA 89 4037 4041
13. P Van de Velde F Nique P Planchon G Prevost J Bremaud MC Hameau V Magnien D Philibert G Teutsch 1996 RU 58668: further in vitro and in vivo pharmacological data related to its antitumoral activity J Steroid Biochem Mol Biol 59 449 457
14. AE Lykkesfeldt 1996 Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer Acta Oncol 35 Suppl 5 9 14
15. RI Nicholson JM Gee 2000 Oestrogen and growth factor cross-talk and endocrine insensitivity and acquired resistance in breast cancer Br J Cancer 82 501 513
16. R Clarke MC Liu KB Bouker Z Gu RY Lee Y Zhu TC Skaar B Gomez K O'Brien Y Wang LA Hilakivi-Clarke 2003 Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling Oncogene 22 7316 7339
17. CK Osborne R Schiff 2003 Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer Breast 12 362 367
18. R Schiff S Massarweh J Shou CK Osborne 2003 Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response Clin Cancer Res 9 447S 454S
19. P Briand AE Lykkesfeldt 1984 Effect of estrogen and antiestrogen on the human breast cancer cell line MCF-7 adapted to growth at low serum concentration Cancer Res 44 1114 1119
20. BK Lundholt P Briand AE Lykkesfeldt 2001 Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways Breast Cancer Res Treat 67 199 214
21. MW Madsen BE Reiter SS Larsen P Briand AE Lykkesfeldt 1997 Estrogen receptor messenger RNA splice variants are not involved in antiestrogen resistance in sublines of MCF-7 human breast cancer cells Cancer Res 57 585 589
22. AM Brown JM Jeltsch M Roberts P Chambon 1984 Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7 Proc Natl Acad Sci USA 81 6344 6348
23. AE Lykkesfeldt MW Madsen P Briand 1994 Altered expression of estrogen-regulated genes in a tamoxifen-resistant and ICI 164,384 and ICI 182,780 sensitive human breast cancer cell line, MCF-7/TAMR-1 Cancer Res 54 1587 1595
24. D McCotter HW van den Berg M Boylan B McKibben 1996 Changes in insulin-like growth factor-I receptor expression and binding protein secretion associated with tamoxifen resistance and estrogen independence in human breast cancer cells in vitro Cancer Lett 99 239 245
25. N Brünner B Boysen S Jirus TC Skaar C Holst-Hansen J Lippman T Frandsen M Spang-Thomsen SA Fuqua R Clarke 1997 MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen Cancer Res 57 3486 3493
26. BL Jensen J Skouv BK Lundholt AE Lykkesfeldt 1999 Differential regulation of specific genes in MCF-7 and the ICI 182780-resistant cell line MCF-7/182R-6 Br J Cancer 79 386 392
27. BL Brockdorff I Heiberg AE Lykkesfeldt 2003 Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha Endocr Relat Cancer 10 579 590
28. AE Lykkesfeldt SS Larsen P Briand 1995 Human breast cancer cell lines resistant to pure anti-estrogens are sensitive to tamoxifen treatment Int J Cancer 61 529 534
29. L Jin M Borras M Lacroix N Legros G Leclercq 1995 Antiestrogenic activity of two 11 beta-estradiol derivatives on MCF-7 breast cancer cells Steroids 60 512 518
30. SR Johnston G Saccani-Jotti IE Smith J Salter J Newby M Coppen SR Ebbs M Dowsett 1995 Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer Cancer Res 55 3331 3338
31. N Brünner TL Frandsen C Holst-Hansen M Bei EW Thompson AE Wakeling ME Lippman R Clarke 1993 MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780 Cancer Res 53 3229 3232
32. A El Khissiin G Leclercq 1999 Implication of proteasome in estrogen receptor degradation FEBS Lett 448 160 166
33. DA Bronzert GL Greene ME Lippman 1985 Selection and characterization of a breast cancer cell line resistant to the antiestrogen LY 117018 Endocrinology 117 1409 1417
34. RG Lapidus SJ Nass NE Davidson 1998 The loss of estrogen and progesterone receptor gene expression in human breast cancer J Mammary Gland Biol Neoplasia 3 85 94
35. S Oesterreich P Zhang RL Guler X Sun EM Curran WV Welshons CK Osborne AV Lee 2001 Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth Cancer Res 61 5771 5777
36. SS Larsen MW Madsen BL Jensen AE Lykkesfeldt 1997 Resistance of human breast-cancer cells to the pure steroidal anti-estrogen ICI 182,780 is not associated with a general loss of estrogen-receptor expression or lack of estrogen responsiveness Int J Cancer 72 1129 1136
37. E Badia MJ Duchesne A Semlali M Fuentes C Giamarchi H Richard-Foy JC Nicolas M Pons 2000 Long-term hydroxytamoxifen treatment of an MCF-7-derived breast cancer cell line irreversibly inhibits the expression of estrogenic genes through chromatin remodeling Cancer Res 60 4130 4138
38. X Cui P Zhang W Deng S Oesterreich Y Lu GB Mills AV Lee 2003 Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer Mol Endocrinol 17 575 588
39. DR Clemmons C Camacho-Hubner E Coronado CK Osborne 1990 Insulin-like growth factor binding protein secretion by breast carcinoma cell lines: correlation with estrogen receptor status Endocrinology 127 2679 2686
40. V Dubois D Couissi E Schonne C Remacle A Trouet 1995 Intracellular levels and secretion of insulin-like-growth-factor-binding proteins in MCF-7/6, MCF-7/AZ and MDA-MB-231 breast cancer cells. Differential modulation by estrogens in serum-free medium Eur J Biochem 232 47 53
41. HS Cho PA NG BS Katzenellenbogen 1991 Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines Mol Endocrinol 5 1323 1330
42. J Jensen JW Kitlen P Briand F Labrie AE Lykkesfeldt 2003 Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium J Steroid Biochem Mol Biol 84 469 478
43. C Donaghue BR Westley FE May 1999 Selective promoter usage of the human estrogen receptor-alpha gene and its regulation by estrogen Mol Endocrinol 13 1934 1950
44. AJ Stewart MD Johnson FE May BR Westley 1990 Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells J Biol Chem 265 21172 21178
45. L Dong W Wang F Wang M Stoner JC Reed M Harigai I Samudio MP Kladde C Vyhlidal S Safe 1999 Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells J Biol Chem 274 32099 32107
46. J Kim LN Petz YS Ziegler JR Wood SJ Potthoff AM Nardulli 2000 Regulation of the estrogen-responsive pS2 gene in MCF-7 human breast cancer cells J Steroid Biochem Mol Biol 74 157 168